The Valley Desk

NCT04209205 · Interventional trial

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

Overall registry status Completed

Phase 3

Conditions Psoriatic Arthritis

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov